Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 12/20 | 0.58 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.55 |
| ▸ | GABRE | P78334 | 1/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.55 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.49 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002433 | 1.00 | CCKBR (0.58) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4704756 | 0.90 | GABRP (0.67) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6005732 | 0.88 | CCKBR (0.59) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7066610 | 0.88 | CCKBR (0.59) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6095803 | 0.87 | CCKBR (0.62) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3287133 | 0.83 | GABRP (0.80) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7064436 | 0.79 | CCKBR (0.54) | CCKBRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7066290 | 0.77 | CCKBR (0.70) | CCKBRNOTCH1NOTCH3KCNH2 | |
| SCHEMBL4411431 | 0.77 | CCKBR (0.70) | CCKBRNOTCH1NOTCH3KCNH2 | |
| SCHEMBL7060759 | 0.77 | OPRK1 (0.71) | CCKBRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | claimed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | claimed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | claimed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | claimed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | claimed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | claimed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | claimed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | CCKBR 3571/4885GABRP 640/4885GABRD 1079/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | CCKBR 3888/4885GABRP 781/4885GABRD 1201/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | CCKBR 3521/4885GABRP 917/4885GABRD 1706/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | CCKBR 3886/4885GABRP 1034/4885GABRD 1461/4885 |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | APP, BACE1, APH1A | CCKBR 3888/4885GABRP 781/4885GABRD 1201/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | CCKBR 3888/4885GABRP 781/4885GABRD 1201/4885 |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | CCKBR 3298/4885GABRP 432/4885GABRD 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.